Fibrinolytics and Antifibrinolytics

ISBN-13: 9783642630293 / Angielski / Miękka / 2012 / 599 str.

F. Bachmann

Opis

In 1978, Fritz Markwardt edited Fibrinolytics and Antifibrinolytics, vol. 46 of the Handbook of Experimental Pharmacology series. Since then tremendous strides have been made in our understanding of the pathophysiology of the fibrinolytic system, of myocardial infarction and of stroke. r am very grateful to the contributors to this new edition of Fibrinolytics and Antifibrinolytics, all outstanding scientists and/or clinicians in their field. They have succeeded in presenting an up-to-date account of basic aspects of the fibrinolytic system, of both older and new thrombolytic agents, and have analyzed in a balanced fashion the results of first to third generation throm bolytic drugs in clinical trials. The book is arranged in three major sections. The first one deals with the molecular biology, biochemistry, physiology and pharmacology of the plas minogen-plasmin enzyme system. The progress that has been made in this field since 1978 is staggering. Methods taken from molecular biology have been used successfully for cloning the zymogen plasminogen, the two princi pal activators and three major inhibitors of the system, many receptors for plasmin( ogen) and its activators, and some modulators of this clot-dissolving system. For many compounds the crystal structure has been uncovered. Numerous regulators of the system, particularly cytokines, growth factors and hormones, have been identified and their action and signal transduction elu cidated. This section is of particular interest to both basic scientists and phar macologists.

Spis treści

Sect. I: Molecular Biology, Biochemistry, Physiology, and Pharmacology of the Plasminogen-Plasmin Enzyme System 1. The Fibrinolytic System and Thrombolytic Agents.- 2. Plasminogen and Streptokinase.- 3. Tissue-type Plasminogen Activator (tPA).- 4. Urinary-type Plasminogen Activator (uPA).- 5. The Inhibitors of the Fibrinolytic System.- 6. Assembly of the Plasminogen System on Cell Surfaces. Section II: Clinical Use of Thrombolytic Agents - In Acute Myocardial Infarction.- 7. Streptokinase and Anisoylated Lys-Plasminogen Streptokinase Activator Complex.- 8. Tissue-type Plasminogen Activator (tPA).- 9. Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase).- 10. Comparative Evaluations of tPA vs SK with Particular Reference to the GUSTO-I Trial.- 11. Conjunctive Therapy to Reduce the Occurrance of Coronary Reocclusion after Thrombolytic Treatment of AMI.- - Thrombolytic Treatment of Other Clinical Thromboembolic Conditions.- 12. New Concepts in Thrombolysis of Pulmonary Embolism.- 13. Deep Venous Thrombosis. 14. Peripheral Arterial Occlusions.- 15. Thrombotic Cerebrovascular Disease.- - Thrombolytic Agents in Development, Biochemistry, Pharmacology, Efficacy in Animal Experiments and First Clinical Trials.- 16. Staphylokinase.- 17. Desmodus rotundus (Common Vampire Bat) Salivary Plasminogen Activator.- 18. Thrombus-Targeting of Plasinogen Activators. 19. The Hunt for the Ideal Thrombolytic Agent: Mutants of tPA and uPA, Chimera of both Molecules, Fibrolase.- 20. Agents which Increase Synthesis and Release of Tissue-Type Plasminogen Activator.- 21. Structure, Pharmacology and Clinical Use of Antifibrinolytic Agents.-